Assembly Biosciences, Inc. (ASMB)
Evaluation: Based on all recent filings, financial statements, and news.
See full evaluationAsk a question about Assembly Biosciences, Inc. (ASMB)
Go deeper and ask any question about ASMB
Company Performance
Current Price
as of Sep 13, 2024$18.07
P/E Ratio
N/A
Market Cap
$114.66M
Description
Assembly Biosciences, Inc. is a biotechnology company, which engages in the development of products for infectious diseases, such as chronic hepatitis B virus and illnesses associated with a dysbiotic microbiome. It focuses on two innovative platform programs: oral therapeutics for the treatment of hepatitis B virus, and the oral synthetic live biotherapeutics candidate. The company was founded by Uri Lopatin and Derek A. Small on October 7, 2005 and is headquartered in South San Francisco, CA.
Metrics
Overview
- HQSouth San Francisco, CA
- SectorHealth Technology
- IndustryPharmaceuticals: Major
- TickerASMB
- Price$18.07+0.17%
Trading Information
- Market Cap$114.66M
- Float70.84%
- Average Daily Volume (1m)20,923
- Average Daily Volume (3m)16,073
- EPS-$8.92
Company
- Revenue$21.48M
- Rev Growth (1yr)N/A
- Net Income-$11.15M
- Gross Margin99.62%
- EBITDA Margin-142.63%
- EBITDA-$12.17M
- EV-$30.05M
- EV/Revenue-1.40
- P/EN/A
- P/S4.75
Documents
SEC Filings
Factset Street Account
Assembly Biosciences reports Q3 EPS ($0.27) vs year-ago ($0.48) ($0.85, 0.00) (2023-11-08T21:25:26Z)
Factset